+ TAC

TAC intervention leads to important legal advance: public interest concerns are relevant in determining interim interdict in patent cases

On 26 July 2012, the Supreme Court of Appeal handed down its judgment in the matter between the Aventis group of pharmaceutical companies and Cipla’s group of generic pharmaceutical companies.

This is the first judgment to decisively say that public interest considerations must be taken into account when balancing the interests of the patentee and the infringer in determining whether or not to grant an interim interdict. The judgment is an important advance in the law that is in line with the values of the Constitution.

SECTION27 intervenes in Aventis v Cipla on behalf of TAC

4 May 2012 The TAC National Council has resolved to seek admission in a legal dispute between the brand name drug company Aventis Pharma and the generic company Cipla, over a claim of patent infringement in respect of a drug…

TAC and SECTION27 release the first issue of our magazine: NSP Review

On World AIDS Day 2011 TAC and SECTION27 launched the first issue of their joint publication, the NSP Review. In this, and in future issues, we aim to provide quality analysis and monitoring of the implementation of the new NSP. It is our hope that this publication will increase awareness of, and critical engagement with the NSP. We will try to keep it relevant with evidence from new research and feedback from the various district offices of the Treatment Action Campaign as well as organisations with which we work closely. Our vision is a vibrant, evidence-based publication that will help all stake holders drive a more successful response to HIV, STIs and TB.

We encourage you to get in touch with us should you want to contribute to future editions of NSP Review.

You can e-mail the editor at nsp@tac.org.za nsp@tac/org.za.

Open letter to HIVEX limited from SECTION27 and the Treatment Action Campaign

Today, World Aids Day 2011, the Treatment Action Campaign (TAC) and SECTION27 submit this open letter and make the following demands to HIVEX Limited (HIVEX). Despite the lack of any scientific evidence that HIVEX treatment is an effective treatment for HIV, HIVEX continues to promote and provide it for this purpose.

It is unlawful and deeply unethical to advertise that HIVEX is an effective treatment for HIV in the absence of such evidence. Antiretroviral treatment remains the only treatment that is scientifically proven to be effective against HIV.